ISSN: 2476-2253

Journal of Cancer Diagnosis
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Case Report   
  • J Cancer Diagn 2018, Vol 3(1): 114
  • DOI: 10.4172/2476-2253.1000114

PD-L1/PD-1 Check Point in Anaplastic Large Cell Lymphoma, ALK+: A Case Report with Immunohistochemical and Molecular Study

Antonella Bianchi1*, Silvia Vallese2 and Ombretta Annibali2
1Unit of Pathology, University Hospital Campus Bio-Medico, Rome, Italy
2Unit of Hematology, Stem Cell Transplantation, Transfusion Medicine and Cellular Therapy, University Hospital Campus Bio-Medico, Rome, Italy
*Corresponding Author : Antonella Bianchi, Unit of Pathology, University Hospital Campus Bio-Medico, Via Alvaro Del Portillo, 200, Rome, Italy, Tel: +(39) 06.22541.1153, Email: a.bianchi@unicampus.it

Received Date: Mar 22, 2018 / Accepted Date: Mar 28, 2018 / Published Date: Apr 05, 2018

Abstract

Anaplastic large cell lymphoma, ALK+ (ALK+ ALCL) is a T-cell lymphoma consisting of large and pleomorphic lymphoid cells, often with horseshoe-shaped nuclei, with a chromosomal translocation involving the ALK gene and expression of ALK protein and CD30. ALK+ ALCL must be distinguished from primary cutaneous ALCL and from other subtype of T-cell or B-cell lymphoma with anaplastic features and/or CD30 expression. PD-L1/PD-1 check point physiologically plays a key role in induction and maintenance of immune tolerance to self-antigens and limits normal immune response against microorganisms. PD-L1 has been demonstrated in the whole spectrum of normal hematopoietic and non-hematopoietic cells, as well as in a large variety of epithelial cells. Moreover, it is also very commonly expressed by a large number of malignant cell types of epithelial and hematopoietic cell origin, and its activation is one of the major mechanisms exerted by neoplastic cells to evade elimination by the host immune system. Here we report a case of an ALK+ ALCL, with confirmed FISH rearrangement of ALK gene, PD-L1-positive and discuss the molecular mechanism involved in its immunohistochemical profile.

Keywords: ALK+ ALCL; PD-L1; PD-1; Lymphomas; Lymphoproliferative Diseases; FISH

Citation: Bianchi A, Vallese S, Annibali O (2018) PD-L1/PD-1 Check Point in Anaplastic Large Cell Lymphoma, ALK+: A Case Report with Immunohistochemical and Molecular Study. J Cancer Diagn 3: 114. Doi: 10.4172/2476-2253.1000114

Copyright: © 2018 Bianchi A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Top